Transcriptional reprogramming during human osteoclast differentiation identifies regulators of osteoclast activity

Abstract

Enhanced osteoclastogenesis and osteoclast activity contribute to the development of osteoporosis, which is characterized by increased bone resorption and inadequate bone formation. As novel antiosteoporotic therapeutics are needed, understanding the genetic regulation of human osteoclastogenesis could help identify potential treatment targets. This study aimed to provide an overview of transcriptional reprogramming during human osteoclast differentiation. Osteoclasts were differentiated from CD14⁺ monocytes from eight female donors. RNA sequencing during differentiation revealed 8 980 differentially expressed genes grouped into eight temporal patterns conserved across donors. These patterns revealed distinct molecular functions associated with postmenopausal osteoporosis susceptibility genes based on RNA from iliac crest biopsies and bone mineral density SNPs. Network analyses revealed mutual dependencies between temporal expression patterns and provided insight into subtype-specific transcriptional networks. The donor-specific expression patterns revealed genes at the monocyte stage, such as filamin B (FLNB) and oxidized low-density lipoprotein receptor 1 (OLR1, encoding LOX-1), that are predictive of the resorptive activity of mature osteoclasts. The expression of differentially expressed G-protein coupled receptors was strong during osteoclast differentiation, and these receptors are associated with bone mineral density SNPs, suggesting that they play a pivotal role in osteoclast differentiation and activity. The regulatory effects of three differentially expressed G-protein coupled receptors were exemplified by in vitro pharmacological modulation of complement 5 A receptor 1 (C5AR1), somatostatin receptor 2 (SSTR2), and free fatty acid receptor 4 (FFAR4/GPR120). Activating C5AR1 enhanced osteoclast formation, while activating SSTR2 decreased the resorptive activity of mature osteoclasts, and activating FFAR4 decreased both the number and resorptive activity of mature osteoclasts. In conclusion, we report the occurrence of transcriptional reprogramming during human osteoclast differentiation and identified SSTR2 and FFAR4 as antiresorptive G-protein coupled receptors and FLNB and LOX-1 as potential molecular markers of osteoclast activity. These data can help future investigations identify molecular regulators of osteoclast differentiation and activity and provide the basis for novel antiosteoporotic targets.

References

[1] Bolamperti S, Villa I, Rubinacci A. Bone remodeling: an operational process ensuring survival and bone mechanical competence. Bone Res, 2022, 10: 48

[2] Arai F et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med, 1999, 190: 1741-1754

[3] Li X et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology, 2002, 143: 3105-3113

[4] Moon JB et al. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J. Immunol, 2012, 188: 163-169

[5] Takayanagi H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell, 2002, 3: 889-901

[6] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423: 337-342

[7] Simonet WS et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309-319

[8] D’Amelio P et al. Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J, 2005, 19: 410-412

[9] Streicher C et al. Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells. Sci. Rep., 2017, 7

[10] D’Amelio P et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone, 2008, 43: 92-100

[11] Eastell R et al. Postmenopausal osteoporosis. Nat. Rev. Dis. Primers, 2016, 2: 16069

[12] Rizzoli R et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif. Tissue Int., 2011, 89: 91-104

[13] Cipriani C, Pepe J, Minisola S, Lewiecki EM. Adverse effects of media reports on the treatment of osteoporosis. J. Endocrinol. Invest., 2018, 41: 1359-1364

[14] Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone, 2011, 49: 103-110

[15] Fink HA et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann. Intern. Med., 2019, 171: 37-50

[16] Møller AMJ et al. Fusion potential of human osteoclasts in vitro reflects age, menopause, and in vivo bone resorption levels of their donors-A possible involvement of DC-STAMP. Int. J. Mol. Sci., 2020, 21: 6368

[17] Hansen MS et al. GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. Eur. J. Endocrinol, 2023, 188: lvac004

[18] Gallois A et al. Genome-wide expression analyses establish dendritic cells as a new osteoclast precursor able to generate bone-resorbing cells more efficiently than monocytes. J. Bone Miner. Res., 2010, 25: 661-672

[19] Lee B, Kim JH, Jung JH, Kim TH, Ji JD. TREM-1, a negative regulator of human osteoclastogenesis. Immunol. Lett, 2016, 171: 50-59

[20] Rashid S et al. Identification of differentially expressed genes and molecular pathways involved in osteoclastogenesis using RNA-seq. Genes (Basel), 2023, 14: 916

[21] Riihonen R et al. Membrane-bound carbonic anhydrases in osteoclasts. Bone, 2007, 40: 1021-1031

[22] Lehenkari P, Hentunen TA, Laitala-Leinonen T, Tuukkanen J, Vaananen HK. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca²⁺. Exp. Cell Res., 1998, 242: 128-137

[23] Dai R et al. Cathepsin K: the action in and beyond bone. Front. Cell Dev. Biol, 2020, 8: 433

[24] Hayman AR. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity, 2008, 41: 218-223

[25] Kikuta J, Ishii M. Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford), 2013, 52: 226-234

[26] Destaing O et al. The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. Mol. Biol. Cell, 2008, 19: 394-404

[27] Arnett TR. Extracellular pH regulates bone cell function. J. Nutr, 2008, 138: 415S-418S

[28] Muñoz-Fuentes V et al. The International Mouse Phenotyping Consortium (IMPC): a functional catalogue of the mammalian genome that informs conservation. Conserv. Genet., 2018, 19: 995-1005

[29] Jemtland R et al. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J. Bone Miner. Res., 2011, 26: 1793-1801

[30] Rumpler M et al. Osteoclasts on bone and dentin in vitro: mechanism of trail formation and comparison of resorption behavior. Calcif. Tissue Int., 2013, 93: 526-539

[31] Zhou Y et al. A novel approach for correction of crosstalk effects in pathway analysis and its application in osteoporosis research. Sci. Rep., 2018, 8

[32] Liu YZ et al. Attenuated monocyte apoptosis, a new mechanism for osteoporosis suggested by a transcriptome-wide expression study of monocytes. PLoS One, 2015, 10: e0116792

[33] Morris JA et al. An atlas of genetic influences on osteoporosis in humans and mice. Nat. Genet, 2019, 51: 258-266

[34] Coates BA et al. Transcriptional profiling of intramembranous and endochondral ossification after fracture in mice. Bone, 2019, 127: 577-591

[35] Balwierz PJ et al. ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs. Genome Res, 2014, 24: 869-884

[36] Ikeda F et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest, 2004, 114: 475-484

[37] Omata Y et al. Interspecies single-cell RNA-seq analysis reveals the novel trajectory of osteoclast differentiation and therapeutic targets. JBMR Plus, 2022, 6: e10631

[38] Musa J, Aynaud MM, Mirabeau O, Delattre O, Grunewald TG. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis., 2017, 8

[39] Signorelli M, Vinciotti V, Wit EC. NEAT: an efficient network enrichment analysis test. BMC Bioinformatics, 2016, 17

[40] McDonald MM et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell, 2021, 184: 1330-1347.e1313

[41] Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov., 2017, 16: 829-842

[42] Diepenhorst N et al. G protein-coupled receptors as anabolic drug targets in osteoporosis. Pharmacol. Ther., 2018, 184: 1-12

[43] Luo J, Sun P, Siwko S, Liu M, Xiao J. The role of GPCRs in bone diseases and dysfunctions. Bone Res., 2019, 7: 19

[44] Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J. Clin. Endocrinol. Metab, 1983, 57: 819-824

[45] Kooistra AJ et al. GPCRdb in 2021: integrating GPCR sequence, structure and function. Nucleic Acids Res., 2021, 49: D335-D343

[46] Luo J et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat. Med., 2016, 22: 539-546

[47] Hauser AS et al. Common coupling map advances GPCR-G protein selectivity. Elife, 2022, 11: e74107

[48] Pandey S et al. Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1. J. Biol. Chem., 2019, 294: 9416-9429

[49] Kovtun A et al. Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair. Sci. Rep., 2017, 7

[50] Modinger Y, Loffler B, Huber-Lang M, Ignatius A. Complement involvement in bone homeostasis and bone disorders. Semin. Immunol, 2018, 37: 53-65

[51] Pobanz JM, Reinhardt RA, Koka S, Sanderson SD. C5a modulation of interleukin-1 beta-induced interleukin-6 production by human osteoblast-like cells. J. Periodontal Res., 2000, 35: 137-145

[52] Gorman DM et al. Development of potent and selective agonists for complement C5a receptor 1 with in vivo activity. J. Med. Chem, 2021, 64: 16598-16608

[53] Woodruff TM et al. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J. Pharmacol. Exp. Ther., 2005, 314: 811-817

[54] Hudson BD et al. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol. Pharmacol., 2013, 84: 710-725

[55] Kim HJ et al. G protein-coupled receptor 120 signaling negatively regulates osteoclast differentiation, survival, and function. J. Cell Physiol., 2016, 231: 844-851

[56] Kasonga AE, Deepak V, Kruger MC, Coetzee M. Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14⁺ monocytes, in vitro. PLoS One, 2015, 10: e0125145

[57] Shimpukade B, Hudson BD, Hovgaard CK, Milligan G, Ulven T. Discovery of a potent and selective GPR120 agonist. J. Med. Chem., 2012, 55: 4511-4515

[58] Rocheville M et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem., 2000, 275: 7862-7869

[59] Bo Q et al. Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues. Cell Discov., 2022, 8: 47

[60] Clowes JA, Allen HC, Prentis DM, Eastell R, Blumsohn A. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J. Clin. Endocrinol. Metab., 2003, 88: 4867-4873

[61] Ren SG et al. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J. Clin. Endocrinol. Metab., 2003, 88: 4239-4245

[62] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 2014, 15

[63] Cody JJ et al. A simplified method for the generation of human osteoclasts in vitro. Int. J. Biochem. Mol. Biol, 2011, 2: 183-189

[64] Sorensen MG et al. Characterization of osteoclasts derived from CD14⁺ monocytes isolated from peripheral blood. J. Bone Miner. Metab., 2007, 25: 36-45

[65] Hassan MQ et al. HOXA10 controls osteoblastogenesis by directly activating bone regulatory and phenotypic genes. Mol. Cell Biol, 2007, 27: 3337-3352

[66] Gordon JA et al. Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors. Mol. Cell Biol, 2010, 30: 3531-3541

[67] Wang Y et al. Obesity regulates miR-467/HoxA10 axis on osteogenic differentiation and fracture healing by BMSC-derived exosome LncRNA H19. J. Cell Mol. Med., 2021, 25: 1712-1724

[68] Blixt N et al. Loss of myocyte enhancer factor 2 expression in osteoclasts leads to opposing skeletal phenotypes. Bone, 2020, 138: 115466

[69] Leupin O et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res., 2007, 22: 1957-1967

[70] D’Angelo R et al. Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor. Biomed. Pharmacother., 2020, 123: 109764

[71] Toyama C et al. Effect of a C5a receptor antagonist on macrophage function in an intestinal transplant rat model. Transpl. Immunol, 2022, 72: 101559

[72] Levaot N et al. Osteoclast fusion is initiated by a small subset of RANKL-stimulated monocyte progenitors, which can fuse to RANKL-unstimulated progenitors. Bone, 2015, 79: 21-28

[73] Hofland LJ, Lamberts SW. Somatostatin receptors and disease: role of receptor subtypes. Baillieres Clin. Endocrinol. Metab., 1996, 10: 163-176

[74] Tulipano G et al. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology, 2002, 143: 1218-1224

[75] Milligan G, Shimpukade B, Ulven T, Hudson BD. Complex pharmacology of free fatty acid receptors. Chem. Rev, 2017, 117: 67-110

[76] Gendaszewska-Darmach E, Drzazga A, Koziolkiewicz M. Targeting GPCRs activated by fatty acid-derived lipids in type 2 diabetes. Trends Mol. Med., 2019, 25: 915-929

[77] Carullo G et al. GPR120/FFAR4 pharmacology: focus on agonists in type 2 diabetes mellitus drug discovery. J. Med. Chem., 2021, 64: 4312-4332

[78] Sorensen KV et al. Effects of delayed-release olive oil and hydrolyzed pine nut oil on glucose tolerance, incretin secretion and appetite in humans. Nutrients, 2021, 13: 3407

[79] Kishikawa A et al. Docosahexaenoic acid inhibits inflammation-induced osteoclast formation and bone resorption in vivo through GPR120 by inhibiting TNF-alpha production in macrophages and directly inhibiting osteoclast formation. Front. Endocrinol (Lausanne), 2019, 10: 157

[80] Ahn SH et al. Free fatty acid receptor 4 (GPR120) stimulates bone formation and suppresses bone resorption in the presence of elevated n-3 fatty acid levels. Endocrinology, 2016, 157: 2621-2635

[81] Wilson SG et al. Common sequence variation in FLNB regulates bone structure in women in the general population and FLNB mRNA expression in osteoblasts in vitro. J. Bone Miner. Res., 2009, 24: 1989-1997

[82] Krakow D et al. Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis. Nat. Genet., 2004, 36: 405-410

[83] Zhou X et al. Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development. Proc. Natl. Acad. Sci. USA, 2007, 104: 3919-3924

[84] Farrington-Rock C et al. Disruption of the Flnb gene in mice phenocopies the human disease spondylocarpotarsal synostosis syndrome. Hum. Mol. Genet., 2008, 17: 631-641

[85] Nakayachi M et al. Lectin-like oxidized low-density lipoprotein receptor-1 abrogation causes resistance to inflammatory bone destruction in mice, despite promoting osteoclastogenesis in the steady state. Bone, 2015, 75: 170-182

[86] Schoenmaker T et al. Transcriptomic differences underlying the activin-a induced large osteoclast formation in both healthy control and fibrodysplasia ossificans progressiva osteoclasts. Int. J. Mol. Sci, 2023, 24: 6822

[87] March DR et al. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol. Pharmacol, 2004, 65: 868-879

[88] Shimon I et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Invest., 1997, 99: 789-798

[89] Merrild DM et al. Pit- and trench-forming osteoclasts: a distinction that matters. Bone Res., 2015, 3: 15032

[90] Dobin A et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 2012, 29: 15-21

[91] Heinz S et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell, 2010, 38: 576-589

[92] Gillespie M et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res., 2022, 50: D687-d692

[93] Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol, 2010, 11

[94] Ritchie ME et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015, 43: e47

[95] Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. bioRxiv, 060012, https://doi.org/10.1101/060012 (2019).

[96] Kavaliauskaite G, Madsen JGS. Automatic quality control of single-cell and single-nucleus RNA-seq using valiDrops. NAR Genom. Bioinform, 2023, 5: lqad101

[97] Hao Y et al. Integrated analysis of multimodal single-cell data. Cell, 2021, 184: 3573-3587.e3529

[98] Soe K, Delaisse JM. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J. Bone Miner. Res., 2010, 25: 2184-2192

[99] Hobolt-Pedersen AS, Delaissé JM, Søe K. Osteoclast fusion is based on heterogeneity between fusion partners. Calcif. Tissue Int., 2014, 95: 73-82

[100] Moura, S. R. et al. Stage-specific modulation of multinucleation, fusion and resorption by the long non-coding RNA DLEU1 and miR-16 in human primary osteoclasts. bioRxiv, 2023.2010.2024.563436, https://doi.org/10.1101/2023.10.24.563436 (2023).

Funding

Lundbeckfonden (Lundbeck Foundation)(R335-2019-2195)

Novo Nordisk Fonden (Novo Nordisk Foundation)(NNF18OC0052699)

Region of Southern Denmark, Vejle, Denmark

Syddansk Universitet (University of Southern Denmark)

Faculty fellowship from University of Southern Denmark, Odense, Denmark. For this funding (one year salary) there is no reference number.

Wellcome Trust (Wellcome)(SBF004|1034)

Odense Universitetshospital (Odense University Hospital)(A3147)